Trials / Recruiting
RecruitingNCT06457477
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
The Safety and Efficacy of Sequential Combination Therapy With PD-1 Antibody and Pegylated Interferon-α in NA-supressed Chronic Hepatitis B Patients
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Beijing 302 Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective study to evaluate the safety and efficacy of Sintilimab (PD-1 antibody) in sequential combination with Peg-IFNα-2b in NA-supressed CHB patients who had previously received Peg-IFNα therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab | 100mg/10ml/1bottle |
| DRUG | NAs | tablets |
| DRUG | Peg-IFNα-2b | 180ug/0.5ml/1bottle |
Timeline
- Start date
- 2024-06-15
- Primary completion
- 2025-12-15
- Completion
- 2025-12-15
- First posted
- 2024-06-13
- Last updated
- 2024-06-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06457477. Inclusion in this directory is not an endorsement.